Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Amortization of Deferred Charges (2019 - 2025)

Cue Biopharma's Amortization of Deferred Charges history spans 6 years, with the latest figure at $10000.0 for Q3 2025.

  • For Q3 2025, Amortization of Deferred Charges changed 0.0% year-over-year to $10000.0; the TTM value through Sep 2025 reached $37000.0, changed 0.0%, while the annual FY2024 figure was $37000.0, 0.0% changed from the prior year.
  • Amortization of Deferred Charges for Q3 2025 was $10000.0 at Cue Biopharma, up from $9000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $10000.0 in Q4 2022 and bottomed at $3000.0 in Q1 2022.
  • The 4-year median for Amortization of Deferred Charges is $9000.0 (2022), against an average of $8800.0.
  • The largest YoY upside for Amortization of Deferred Charges was 200.0% in 2023 against a maximum downside of 10.0% in 2023.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $10000.0 in 2022, then dropped by 10.0% to $9000.0 in 2023, then changed by 0.0% to $9000.0 in 2024, then increased by 11.11% to $10000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Amortization of Deferred Charges are $10000.0 (Q3 2025), $9000.0 (Q2 2025), and $9000.0 (Q1 2025).